Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | THPO | P40225 | 2/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | GLA | P06280 | 1/20 | 0.78 |
| ▸ | EIF4E | P06730 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | TOP1 | P11387 | 1/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.78 |
| ▸ | PNP | P00491 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566208 | 1.00 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL15155278 | 1.00 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL11368948 | 0.88 | LMNA (0.95) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL3727 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL5476700 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL4064991 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL12901991 | 0.88 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL21311208 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL20806078 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL13320541 | 0.88 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0374096-A1 | Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | claimed |
| EP-0233493-A2 | Process for producing ribonucleosides | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-08-26 | — | — | EP | claimed |
| EP-1971690-B1 | TRANSLATIONAL DYSFUNCTION BASED THERAPEUTICS | TRANSLATIONAL THERAPEUTICS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2067034-B1 | EIF4E REGULON-BASED DIAGNOSTICS | TRANSLATIONAL THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20140363396-A1 | ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN | KADMON PHARMACEUTICALS LLC (US) | 2014-12-11 | — | — | US | disclosed |
| EP-2762886-A1 | EIF4E Regulon-based diagnostics | Translational Therapeutics, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8497292-B2 | Translational dysfunction based therapeutics | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20090163564-A1 | Translational Dysfunction Based Therapeutics | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2067034-A2 | EIF4E REGULON-BASED DIAGNOSTICS | Translational Therapeutics, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1971690-A2 | TRANSLATIONAL DYSFUNCTION BASED THERAPEUTICS | Translational Therapeutics (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008060369-A2 | EIF4E REGULON-BASED DIAGNOSTICS | TRANSLATIONAL THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| CN-1718182-A | Use of vegetable flavonoid | GUANGDONG PROV EX ANIMAL MONIT (CN) | 2006-01-11 | — | — | CN | disclosed |
| EP-1414836-B1 | PROCESS FOR THE PREPARATION OF L-RIBAVIRIN | CLARIANT LSM ITALIA SPA (IT) | 2004-12-29 | — | — | EP | disclosed |
| US-20040192904-A1 | Process for the preparation of ribavirin | ARCHIMICA S.R.L. (IT) | 2004-09-30 | — | — | US | disclosed |
| EP-1414836-A2 | PROCESS FOR THE PREPARATION OF L-RIBAVIRIN | Clariant Life Science Molecules (Italia) SpA (IT) | 2004-05-06 | — | — | EP | disclosed |
| EP-1281715-B1 | Process for the preparation of ribavirin | CLARIANT LSM ITALIA SPA (IT) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003011883-A2 | PROCESS FOR THE PREPARATION OF L-RIBAVIRIN | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011884-A1 | PROCESS FOR THE PREPARATION OF RIBAVIRIN | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2003-02-13 | — | — | WO | disclosed |
| EP-1281715-A1 | Process for the preparation of ribavirin | Clariant Life Science Molecules (Italia) SpA (IT) | 2003-02-05 | — | — | EP | disclosed |
| EP-0233493-A2 | Process for producing ribonucleosides | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363396-A1 | ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN | HAVCR2, IFNG, EIF2AK2 | LMNA 3874/4885SMN1; SMN2 3916/4885ALDH1A1 1211/4885 |
| US-20090163564-A1 | Translational Dysfunction Based Therapeutics | EIF4EBP1, EIF4E, EIF4A1 | LMNA 3062/4885SMN1; SMN2 699/4885ALDH1A1 4492/4885 |
| US-20040192904-A1 | Process for the preparation of ribavirin | CPSF1, RNGTT, CPSF7 | LMNA 1378/4885SMN1; SMN2 3161/4885ALDH1A1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.